| 31.10 12:31 | dpa-AFX: Regeneron Pharmaceuticals Q3 24 Earnings Conference Call At 8:30 AM ET |
| 31.10 11:50 | dpa-AFX: Regeneron Pharmaceuticals Q3 Profit Increases, Beats Estimates |
| 31.10 11:48 | dpa-AFX: *REGENERON PHARMA Q3 GAAP NET INCOME $1.34 BLN; NON-GAAP NET INCOME $1.46 BLN |
| 31.10 11:48 | dpa-AFX: *REGENERON PHARMA Q3 GAAP EPS $11.54 AND NON-GAAP EPS $12.46 |
| 31.10 11:34 | dpa-AFX: *REGENERON PHARMA Q3 REVENUES UP 11% TO $3.72 BLN |
| 19.10 00:27 | dpa-AFX: Regeneron : EYLEA HD Three-Year Results Show Lasting Vision Gains In Diabetic Macular Edema Patients |
| 07.10 14:30 | dpa-AFX: Regeneron Pharmaceuticals: IPR&D Charge To Negatively Impact Q3 EPS By Approx. $0.43 |
| 07.10 14:19 | dpa-AFX: *REGENERON ANTICIPATES $56 MLN ACQUIRED IN-PROCESS R&D CHARGE IN Q3 |
| 27.09 16:51 | dpa-AFX: Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment |
| 27.09 16:11 | Sanofi und Regeneron erhalten US-Zulassung für Dupixent bei COPD |
| 27.09 15:52 | dpa-AFX: *REGENERON & SANOFI : DUPIXENT APPROVED IN U.S. FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT |
| 27.09 13:36 | dpa-AFX: Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease |
| 27.09 13:05 | dpa-AFX: *REGENERON PHARMA AND SANOFI: NMPA IN CHINA APPROVES DUPIXENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| 20.09 14:02 | dpa-AFX: *SANOFI: DUPIXENT RECOMMENDED BY CHMP FOR EU APPROVAL TO TREAT EOSINOPHILIC ESOPHAGITIS IN KIDS |
| 11.09 07:54 | Sanofi-Medikament Dupixent mit Studienerfolg bei Hautkrankheiten |
| 11.09 07:28 | dpa-AFX: Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints |
| 10.09 05:26 | dpa-AFX: Regeneron's Five-Year Phase 3 Trial Shows Durable Survival Benefit Of Libtayo In PD-L1 High NSCLC |
| 26.08 19:20 | MÄRKTE USA/Uneinheitlich - Technologiewerte mit Abgaben |
| 26.08 18:38 | MÄRKTE USA/Uneinheitlich - Technologiewerte mit Abgaben |
| 26.08 15:44 | MÄRKTE USA/Leicht positiv - Weitere US-Daten und Nvidia-Zahlen im Blick |
|
|
